To order HYALGAN®, please call 1-888-838-7687 or click here to order online.
First time ordering? Create an account now.

For more information regarding Hyalgan, or to have a Representative contact you,
please contact us.

Reimbursement support for you and your patients

HYALGAN® Reimbursement HOTLINE:*

1-800-992-9022

Available Monday-Friday,

9 AM to 8 PM ET

HYALGAN® is covered by Medicare and most managed care plans

Assists in obtaining prior authorization for treatment
Verifies patient insurance coverage
Provides payer policy research and coding information
Assists with claim submissions, reviews, and reconciliations
Identifies alternate sources of reimbursement for eligible patients
Qualifies and enrolls eligible patient in the HYALGAN® Patient Assistance Program

National CPCS code: J7321

*The Hotline dos not file claims or appeal claims for callers, nor can it guarantee that you will be successful in obtaining reimbursement. Third-party payment for medical products and services is affected by numerous factors, not all of which can be anticipated or resolved by the Hotline.

The HYALGAN® Reimbursement Guide provides complete information. Link to download HYALGAN® Reimbursement Guide Download a printable version of the Guide.

To download the Reimbursement Guide, you will need Adobe Reader. Download the Free Adobe Reader now.

Web sites and other resources
Get HYALGAN® Updates

Important Safety Information for HYALGAN®

HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpha-rmacologic therapy, and to simple analgesics, eg, acetaminophen
HYALGAN® is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site
The effectiveness of a single treatment cycle of less than 3 injections has not been established
In the US clinical trial of 495 patients, the only adverse event showing statistical significance vs placebo was injection-site pain
Other adverse events included gastrointestinal complaints, headache, local ecchymosis and rash, local joint pain and swelling, and local pruritus. However, the incidence of these events was similar in the HYALGAN®-treated and placebo groups
In other clinical studies, the frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle

Click here for additional important information for HYALGAN®.